These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 9028057)

  • 1. Opioid-immune interactions in autism: behavioural and immunological assessment during a double-blind treatment with naltrexone.
    Scifo R; Cioni M; Nicolosi A; Batticane N; Tirolo C; Testa N; Quattropani MC; Morale MC; Gallo F; Marchetti B
    Ann Ist Super Sanita; 1996; 32(3):351-9. PubMed ID: 9028057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Opiate hypothesis in infantile autism? Therapeutic trials with naltrexone].
    Leboyer M; Bouvard MP; Launay JM; Recasens C; Plumet MH; Waller-Perotte D; Tabuteau F; Bondoux D; Dugas M
    Encephale; 1993; 19(2):95-102. PubMed ID: 8275903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naltrexone and communication skills in young children with autism.
    Feldman HM; Kolmen BK; Gonzaga AM
    J Am Acad Child Adolesc Psychiatry; 1999 May; 38(5):587-93. PubMed ID: 10230191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma beta-endorphin levels, naltrexone, and haloperidol in autistic children.
    Ernst M; Devi L; Silva RR; Gonzalez NM; Small AM; Malone RP; Campbell M
    Psychopharmacol Bull; 1993; 29(2):221-7. PubMed ID: 8290669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study.
    Willemsen-Swinkels SH; Buitelaar JK; van Engeland H
    Biol Psychiatry; 1996 Jun; 39(12):1023-31. PubMed ID: 8780837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naltrexone in young autistic children: a double-blind, placebo-controlled crossover study.
    Kolmen BK; Feldman HM; Handen BL; Janosky JE
    J Am Acad Child Adolesc Psychiatry; 1995 Feb; 34(2):223-31. PubMed ID: 7896655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naltrexone in young autistic children: replication study and learning measures.
    Kolmen BK; Feldman HM; Handen BL; Janosky JE
    J Am Acad Child Adolesc Psychiatry; 1997 Nov; 36(11):1570-8. PubMed ID: 9394942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of pruritus with topically applied opiate receptor antagonist.
    Bigliardi PL; Stammer H; Jost G; Rufli T; Büchner S; Bigliardi-Qi M
    J Am Acad Dermatol; 2007 Jun; 56(6):979-88. PubMed ID: 17320241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Review of psychopharmacological treatments in adolescents and adults with autistic disorders].
    Baghdadli A; Gonnier V; Aussilloux C
    Encephale; 2002; 28(3 Pt 1):248-54. PubMed ID: 12091786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical effects of naltrexone on autistic behavior.
    Zingarelli G; Ellman G; Hom A; Wymore M; Heidorn S; Chicz-DeMet A
    Am J Ment Retard; 1992 Jul; 97(1):57-63. PubMed ID: 1497864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naltrexone in autistic children: a double-blind and placebo-controlled study.
    Campbell M; Anderson LT; Small AM; Locascio JJ; Lynch NS; Choroco MC
    Psychopharmacol Bull; 1990; 26(1):130-5. PubMed ID: 2196621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of a serious autistic disorder in a child with Naltrexone in an oral suspension form].
    Desjardins S; Doyen C; Contejean Y; Kaye K; Paubel P
    Encephale; 2009 Apr; 35(2):168-72. PubMed ID: 19393386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Opiate hypothesis of the origin of early childhood autism and sequelae for psychopharmacotherapy].
    Lensing P; Klingler D; Panksepp J; Huber M; Saria A; Hackenberg B; Adam H
    Z Kinder Jugendpsychiatr; 1992 Sep; 20(3):185-96. PubMed ID: 1329399
    [No Abstract]   [Full Text] [Related]  

  • 14. A double-blind, placebo-controlled study of the opiate antagonist, naltrexone, in the treatment of kleptomania.
    Grant JE; Kim SW; Odlaug BL
    Biol Psychiatry; 2009 Apr; 65(7):600-6. PubMed ID: 19217077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial.
    Akhondzadeh S; Erfani S; Mohammadi MR; Tehrani-Doost M; Amini H; Gudarzi SS; Yasamy MT
    J Clin Pharm Ther; 2004 Apr; 29(2):145-50. PubMed ID: 15068403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of naltrexone use in pediatric patients with autistic disorder.
    Elchaar GM; Maisch NM; Augusto LM; Wehring HJ
    Ann Pharmacother; 2006 Jun; 40(6):1086-95. PubMed ID: 16735648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Psychopharmacology of autism].
    Chabrol H; Bonnet D; Roge B
    Encephale; 1996; 22(3):197-203. PubMed ID: 8767048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Placebo-controlled acute dosage naltrexone study in young autistic children.
    Willemsen-Swinkels SH; Buitelaar JK; Weijnen FG; van Engeland H
    Psychiatry Res; 1995 Oct; 58(3):203-15. PubMed ID: 8570776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naltrexone in children with autism.
    Buitelaar JK; Willemsen-Swinkels S; Van Engeland H
    J Am Acad Child Adolesc Psychiatry; 1998 Aug; 37(8):800-2. PubMed ID: 9695440
    [No Abstract]   [Full Text] [Related]  

  • 20. Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study.
    Bouvard MP; Leboyer M; Launay JM; Recasens C; Plumet MH; Waller-Perotte D; Tabuteau F; Bondoux D; Dugas M; Lensing P
    Psychiatry Res; 1995 Oct; 58(3):191-201. PubMed ID: 8570775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.